BR112013027150A2 - thera - Google Patents
theraInfo
- Publication number
- BR112013027150A2 BR112013027150A2 BR112013027150A BR112013027150A BR112013027150A2 BR 112013027150 A2 BR112013027150 A2 BR 112013027150A2 BR 112013027150 A BR112013027150 A BR 112013027150A BR 112013027150 A BR112013027150 A BR 112013027150A BR 112013027150 A2 BR112013027150 A2 BR 112013027150A2
- Authority
- BR
- Brazil
- Prior art keywords
- grf
- growth hormone
- analogues
- leucine
- releasing factor
- Prior art date
Links
- 241000011102 Thera Species 0.000 title 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 2
- 101710142969 Somatoliberin Proteins 0.000 abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
resumo da patente de invenção para: análogos de fator de liberação de hormônio de crescimento (grf) e usos dos mesmos. são descritos aqui análogos de fator de liberação de hormônio de crescimento (grf) em que lisina-21, leucina-22 e leucina-23 são deletadas nos mesmos. estes análogos retêm atividade de grf. os usos dos ditos análogos, por exemplo, como um agonista de receptor de grf, por exemplo, para induzir secreção de hormônio de crescimento em um sujeito ou sistema biológico são também descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477775P | 2011-04-21 | 2011-04-21 | |
PCT/CA2012/050242 WO2012142706A1 (en) | 2011-04-21 | 2012-04-17 | Growth hormone releasing factor (grf) analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013027150A2 true BR112013027150A2 (pt) | 2017-06-06 |
Family
ID=47021786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013027150A BR112013027150A2 (pt) | 2011-04-21 | 2012-04-17 | thera |
Country Status (10)
Country | Link |
---|---|
US (1) | US8361964B2 (pt) |
EP (1) | EP2699591A4 (pt) |
JP (1) | JP6113144B2 (pt) |
KR (1) | KR20140027284A (pt) |
CN (1) | CN103547591A (pt) |
AR (1) | AR087727A1 (pt) |
BR (1) | BR112013027150A2 (pt) |
CA (1) | CA2833434A1 (pt) |
MX (1) | MX2013012259A (pt) |
WO (1) | WO2012142706A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
PT3445778T (pt) | 2016-04-19 | 2020-10-15 | Griffon Pharmaceuticals Int Sa C/O Biopole Sa | Péptidos bioativos peguilados e suas utilizações |
EP4175661A1 (en) * | 2020-07-05 | 2023-05-10 | Theratechnologies Inc. | Low-dose pharmaceutical compositions of ghrh analogs and uses thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518586A (en) | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
US4617149A (en) | 1983-09-21 | 1986-10-14 | Eli Lilly And Company | Growth hormone release factor analogs |
US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
US4734399A (en) * | 1985-08-06 | 1988-03-29 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
US4801456A (en) | 1987-07-09 | 1989-01-31 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
ES2054754T3 (es) * | 1987-09-18 | 1994-08-16 | Hoffmann La Roche | Analogos ciclicos del grf. |
NZ237857A (en) * | 1990-04-24 | 1992-05-26 | Lilly Co Eli | Polypeptide compounds with growth hormone releasing factor activity |
JPH05507939A (ja) | 1991-04-09 | 1993-11-11 | エフ・ホフマン―ラ ロシユ アーゲー | 成長ホルモン放出因子の類似体 |
US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
EP0820296A4 (en) | 1995-04-14 | 1999-06-30 | Univ Tulane | ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR |
AU697119B2 (en) | 1995-05-26 | 1998-09-24 | Theratechnologies Inc. | Chimeric fatty body-pro-GRF analogs with increased biological potency |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
EP1324777A1 (en) | 2000-10-05 | 2003-07-09 | Ares Trading S.A. | Regioselective liquid phase pegylation |
JP2004520395A (ja) | 2001-02-02 | 2004-07-08 | コンジュケム,インコーポレーテッド | 長期持続性成長ホルモン放出因子誘導体 |
DK1401863T3 (da) * | 2001-06-08 | 2009-05-25 | Ipsen Pharma | Kimære somatostatin-dopamin-analoge |
BR0314619A (pt) | 2002-09-18 | 2005-08-02 | Univ Montreal Ct Hospitalier Chum | Análogos de ghrh |
CA2527039C (en) | 2003-05-29 | 2013-07-09 | Theratechnologies Inc. | Grf analog compositions and their use |
TW200517400A (en) | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
WO2005037307A1 (en) | 2003-10-20 | 2005-04-28 | Theratechnologies Inc. | Use of growth hormone releasing factor analogs in treating patients suffering from wasting |
EP1812048A4 (en) | 2004-10-20 | 2012-01-18 | Theratechnologies Inc | GH SECRETAGOGA AND ITS USE |
US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
US20090088380A1 (en) | 2007-07-12 | 2009-04-02 | Pierrette Gaudreau | Ghrh analogs and therapeutic uses thereof |
US20110021429A1 (en) | 2007-10-01 | 2011-01-27 | Pierrette Gaudreau | Renoprotection by growth hormone-releasing hormone and agonists |
WO2010121352A1 (en) | 2009-04-20 | 2010-10-28 | Theratechnologies Inc. | Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy |
-
2012
- 2012-04-17 CN CN201280024235.3A patent/CN103547591A/zh active Pending
- 2012-04-17 CA CA2833434A patent/CA2833434A1/en not_active Abandoned
- 2012-04-17 US US13/448,660 patent/US8361964B2/en not_active Expired - Fee Related
- 2012-04-17 KR KR1020137030657A patent/KR20140027284A/ko not_active Application Discontinuation
- 2012-04-17 JP JP2014505470A patent/JP6113144B2/ja not_active Expired - Fee Related
- 2012-04-17 EP EP12774217.9A patent/EP2699591A4/en not_active Withdrawn
- 2012-04-17 MX MX2013012259A patent/MX2013012259A/es active IP Right Grant
- 2012-04-17 BR BR112013027150A patent/BR112013027150A2/pt not_active IP Right Cessation
- 2012-04-17 WO PCT/CA2012/050242 patent/WO2012142706A1/en active Application Filing
- 2012-04-19 AR ARP120101345A patent/AR087727A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20120270784A1 (en) | 2012-10-25 |
EP2699591A4 (en) | 2014-05-07 |
MX2013012259A (es) | 2013-11-22 |
JP6113144B2 (ja) | 2017-04-12 |
JP2014515751A (ja) | 2014-07-03 |
WO2012142706A1 (en) | 2012-10-26 |
KR20140027284A (ko) | 2014-03-06 |
AR087727A1 (es) | 2014-04-16 |
CN103547591A (zh) | 2014-01-29 |
US8361964B2 (en) | 2013-01-29 |
CA2833434A1 (en) | 2012-10-26 |
EP2699591A1 (en) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
PH12014502778B1 (en) | Antibody formulation | |
CL2014003421A1 (es) | Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. | |
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
CL2015001256A1 (es) | Compuestos derivados del acido indaniloxi-dihidro-benzofuranil-acetico, agonistas del receptor acoplado a proteinas g40 (gpr40); sal; composicion farmaceutica; y uso para profilaxis y/o terapia de enfermedades metabolicas tales como diabetes y sus afecciones asociadas tales como resistencia a la insulina y obesidad, entre otras. | |
BR112014026057A2 (pt) | análogos limitados por anel como inibidores de arginase | |
PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
BR112012032282A2 (pt) | administração transdérmica de memantina | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CL2013002933A1 (es) | Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal | |
CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
CL2012000026A1 (es) | Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus. | |
SV2010003581A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
CR20150360A (es) | Sistema de liberación transdérmica | |
BR112013014616A2 (pt) | sistema terapêutico transdérmico para a administração de uma substância ativa | |
CL2013002129A1 (es) | Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras. | |
CL2015001652A1 (es) | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. | |
CO6920294A2 (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
CL2014000289A1 (es) | Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica. | |
BR112013027150A2 (pt) | thera |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12/02/2019. |